rspНаучно-практическая ревматологияRheumatology Science and Practice1995-44841995-4492IMA-PRESS, LLC10.14412/1995-4484-2017-580-581rsp-2444Research ArticleДИСКУССИИDISCUSSIONДискуссионные представления о двусмысленности медициныDISCUSSION IDEAS ABOUT MEDICINE AMBIGUITIESМуравьевЮ. В.MuravyevYu. V.

115522 Москва, Каширское шоссе, 34А

34A, Kashirskoe Shosse, Moscow 115522

murawyu@mail.ruМуравьеваЛ. А.MuravyevL. A.

141400 Московская область, Химки, ул. Чкалова, 2/21

2/21, Chkalov St., Khimki, Moscow Region 141400

ФГБНУ «Научно- исследовательский институт ревматологии им. В.А. Насоновой»РоссияV.A. Nasonova Research Institute of RheumatologyRussian FederationЦентральное поликлиническое отделение МБУЗ «Химкинская центральная клиническая больница»РоссияCentral Polyclinic Department, Khimki Central Clinical HospitalRussian Federation201727102017555580581Copyright © Муравьев Ю.В., Муравьева Л.А., 20172017Муравьев Ю.В., Муравьева Л.А.Muravyev Y.V., Muravyev L.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://rsp.mediar-press.net/rsp/article/view/2444

Обсуждаются дискуссионные представления о возможных причинах неопределенности в медицине, возникшей в эпоху цифровых технологий и информационного наводнения

The paper considers discussion ideas about the possible causes of medicine uncertainty that arose in the era of digital technologies and information flooding.

цифровые технологиирандомизированные клинические испытаниянеблагоприятные реакцииолигополиягенно-инженерные биологические препаратыdigital technologiesrandomized clinical trialsadverse eventsoligopolybiological agents.ReferencesUnnikrishnan MK. Eminence or Evidence? The Volatility, Uncertainty, Complexity, and Ambiguity in Healthcare. J Pharmacol Pharmacother. 2017;8(1):1-2. doi: 10.4103/jpp.JPP_12_17Unnikrishnan MK. Eminence or Evidence? The Volatility, Uncertainty, Complexity, and Ambiguity in Healthcare. J Pharmacol Pharmacother. 2017;8(1):1-2. doi: 10.4103/jpp.JPP_12_17Golder S, Loke YK, Wright K, Norman G. Reporting of adverse events in published and unpublished studies of health care interventions: A systematic review. PLoS Med. 2016;13:e1002127.Golder S, Loke YK, Wright K, Norman G. Reporting of adverse events in published and unpublished studies of health care interventions: A systematic review. PLoS Med. 2016;13:e1002127.Lundh A, Sismondo S, Lexchin J, et al. Industry sponsorship and research outcome. Cochrane Database of Systematic Reviews 2012;12: MR000033. doi: 10.1002/14651858.MR000033.pub2Lundh A, Sismondo S, Lexchin J, et al. Industry sponsorship and research outcome. Cochrane Database of Systematic Reviews 2012;12: MR000033. doi: 10.1002/14651858.MR000033.pub2ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the Antihypertensive and Lipid- Lowering Treatment to Prevent Heart Attack Trial (ALLHATLLT). JAMA. 2002;288(23):2998-3007. doi: 10.1001/jama.288.23.2998ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the Antihypertensive and Lipid- Lowering Treatment to Prevent Heart Attack Trial (ALLHATLLT). JAMA. 2002;288(23):2998-3007. doi: 10.1001/jama.288.23.2998Han BH, Sutin D, Williamson JD, et al. Effect of statin treatment vs usual careon primary cardiovascular prevention among older adults the ALLHAT-LLT randomized clinical trial. JAMA Intern Med. 2017 May 22. doi: 10.1001/jamainternmed.2017.1442 [Epub ahead of print].Han BH, Sutin D, Williamson JD, et al. Effect of statin treatment vs usual careon primary cardiovascular prevention among older adults the ALLHAT-LLT randomized clinical trial. JAMA Intern Med. 2017 May 22. doi: 10.1001/jamainternmed.2017.1442 [Epub ahead of print].Abramson JD, Rosenberg HG, Jewell N, Wright JM. Should people at low risk of cardiovascular disease take a statin? BMJ. 2013;347:f6123. doi: 10.1136/bmj.f6123Abramson JD, Rosenberg HG, Jewell N, Wright JM. Should people at low risk of cardiovascular disease take a statin? BMJ. 2013;347:f6123. doi: 10.1136/bmj.f6123Collins R, Reith C, Emberson J, et al. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet. 2016;388:2532-61. doi: 10.1016/S0140-6736(16)31357-5Collins R, Reith C, Emberson J, et al. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet. 2016;388:2532-61. doi: 10.1016/S0140-6736(16)31357-5Heath I, Evans S, Furberg C, et al. Report of the independent panel considering the retraction of two articles in the BMJ. BMJ. 2014;349:g5176. doi: 10.1136/bmj.g5176Heath I, Evans S, Furberg C, et al. Report of the independent panel considering the retraction of two articles in the BMJ. BMJ. 2014;349:g5176. doi: 10.1136/bmj.g5176Holleman F, Uijldert M, Donswijk LF, Gale EA. Productivity of authors in the field of diabetes: Bibliographic analysis of trial publications. BMJ. 2015;351:h2638. doi: 10.1136/bmj.h2638Holleman F, Uijldert M, Donswijk LF, Gale EA. Productivity of authors in the field of diabetes: Bibliographic analysis of trial publications. BMJ. 2015;351:h2638. doi: 10.1136/bmj.h2638Zink A, Strangfeld A, Schneider M, et al. Effectiveness of tumor necrosis factor inhibitors in rheumatoid arthritis in an observational cohort study: comparison of patients according to their eligibility for major randomized clinical trials. Arthritis Rheum. 2006;54:3399-407. doi: 10.1002/art.22193Zink A, Strangfeld A, Schneider M, et al. Effectiveness of tumor necrosis factor inhibitors in rheumatoid arthritis in an observational cohort study: comparison of patients according to their eligibility for major randomized clinical trials. Arthritis Rheum. 2006;54:3399-407. doi: 10.1002/art.22193Aaltonen KJ, Ylikylä S, Tuulikki Joensuu J, et al. Efficacy and effectiveness of tumour necrosis factor inhibitors in the treatment of rheumatoid arthritis in randomized controlled trials and routine clinical practice. Rheumatology (Oxford). 2017;56(5):725-35. doi: 10.1093/rheumatology/kew467Aaltonen KJ, Ylikylä S, Tuulikki Joensuu J, et al. Efficacy and effectiveness of tumour necrosis factor inhibitors in the treatment of rheumatoid arthritis in randomized controlled trials and routine clinical practice. Rheumatology (Oxford). 2017;56(5):725-35. doi: 10.1093/rheumatology/kew467

The authors declare that there are no conflicts of interest present.